To investigate the fraction of cancer initiating cells in lung cancer cell line A549 by cloning and tumorigenic analyses.
目的通过克隆形成及致瘤能力研究肺腺癌细胞系a549肿瘤始发细胞的比例。
Objective To establish a successful xenotransplantation model of a human small cell lung cancer cell line (NCI_H446) in nude mice.
目的建立成瘤稳定、潜伏期短的人小细胞肺癌nci_h4 4 6细胞裸鼠移植瘤模型。
Objective: To study the effects on proliferation inhibition and anti-invasion of glycyrrhizin in highly metastasis lung cancer cell line (PGCL3).
目的：探讨甘草酸对高转移人肺癌细胞(PGCL3)增殖抑制和抗侵袭的作用。
The researchers tested the flying carpet drug delivery technique in preclinical trials against human lung cancer tumors (cell line A549) in laboratory mice.
研究人员针对人肺癌肿瘤(A549细胞)在实验室小鼠临床实验中测试了飞毯药物输送技术。
To investigate the effects of tumor suppressor in lung cancer-1 (TSLC1) on cell aggression, tumor formation and capability of metastasis in human prostatic carcinoma cell line T3B.
研究肺癌抑癌基因1 (TSLC1)对人前列腺癌t 3 B细胞侵袭、成瘤和转移能力的影响。
The latest progresses of pemetrexed in first-line treatment, second-line treatment, maintenance treatment, and adjuvant chemotherapy of non-small cell lung cancer are reviewed in the article.
本文对此药在非小细胞肺癌一线、二线、维持治疗和辅助放化疗方面最新的研究进展进行了回顾和展望。
Objective To study the inhibition of lung cancer cells of primary culture and A549 cell line on the proliferation of tumor-infiltrating lymphocytes (TIL) in vitro and its clinical implications.
目的研究肺癌原代细胞和细胞系a549对肿瘤浸润性淋巴细胞的抑制作用及其临床意义。
Objective To evaluate the efficacy and toxicity of irinotecan combined with nedaplatin in second-line therapy of small-cell lung cancer.
目的观察伊立替康联合奈达铂二线治疗小细胞肺癌的疗效及毒副反应。
Background: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer.
背景：此前的无对照研究显示肺癌一线治疗联合吉非替尼治疗非小细胞肺癌是有效的。
Purpose Doublet chemotherapy is more effective than single-agent as first-line treatment of advanced non-small-cell lung cancer (NSCLC).
目的：在进展期非小细胞肺癌(NSCLC)患者一线化疗中，双药联合比但要更有效。
Background and Objective: Docetaxel combined with cisplatin is established as first-line therapy for advanced non-small cell lung cancer (NSCLC).
背景与目的：多西紫杉醇联合顺铂被确定为治疗晚期非小细胞肺癌的一线方案之一。
METHODS: cell line A549 and GLC-82 originated from human non-small cell lung cancer were cultured in vitro. Study group (2-me in different concentrations) and control group without 2-me were set up.
方法：将体外培养的人肺癌细胞A549和GLC- 82分为实验组和对照组，其中实验组加入不同浓度的2 -ME，对照组不含2 - ME。
Tarceva approved in US and EU for first-line treatment of non-small-cell lung cancer after chemotherapy.
特罗凯在美国和欧盟被批准用于非小细胞肺癌化疗后一线治疗。
Tarceva approved in US and EU for first-line treatment of non-small-cell lung cancer after chemotherapy.
特罗凯在美国和欧盟被批准用于非小细胞肺癌化疗后一线治疗。
应用推荐